- According to National Comprehensive Cancer Network (NCCN) guidelines:
- Risk reducing mastectomy (RRM):
- Should be routinely discussed with all of the following:
- BRCA 1
- BRCA 2
- Li-Fraumeni syndrome
- PTEN
- History of mantle radiation prior to age 30
- CHEK2 mutations do not require a RRM:
- There is insufficient evidence in CHEK2 mutations to routinely recommend RRM
- Should be routinely discussed with all of the following:
- Risk reducing mastectomy (RRM):
- Risk-reducing mastectomy:
- Has been shown to decrease the incidence of breast cancer by 90% or more in several studies
- References
- Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454-468.
- NCCN Guideline with NCCN Evidence Blocks™ – Breast Cancer Version 3.2019. National Comprehensive Cancer Network website. https://www.nccn.org/professionals/physician_gls/recently_updated.aspx. Accessed September 21, 2019.
- Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062.
- Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967-975.
#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #CASO #Miami #CenterforAdvancedSurgicalOncology #BRCA #RRM #RiskReducingMastectomy
Rodrigo Arrangoiz MS, MD, FACS, FSSO 